Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032506 | 0.84 | CA12 (0.55) | RAB9ATACR1SIGMAR1CA12CA1 | |
| SCHEMBL2700497 | 0.81 | NPC1 (0.63) | NPC1TDP1ALDH1A1MAPTFKBP1A | |
| SCHEMBL18068774 | 0.81 | OPRM1 (0.62) | RAB9ATACR1CA12CA1CA2 | |
| SCHEMBL13593925 | 0.79 | NPC1 (0.60) | NPC1TDP1ALDH1A1MAPTFKBP1A | |
| SCHEMBL4818498 | 0.79 | AR (0.55) | ARNPC1RAB9ATDP1SIGMAR1 | |
| SCHEMBL4818508 | 0.79 | AR (0.55) | ARNPC1RAB9ATDP1SIGMAR1 | |
| SCHEMBL2473435 | 0.78 | CHRM5 (0.53) | KCNA3SIGMAR1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL6032504 | 0.77 | CA12 (0.54) | RAB9ATACR1CA12CA1CA2 | |
| SCHEMBL8599293 | 0.77 | NPC1 (0.81) | ARNPC1RAB9ATDP1SIGMAR1 | |
| SCHEMBL13774957 | 0.77 | CA12 (0.59) | RAB9ACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | claimed |
| EP-1599447-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076418-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-09-10 | — | — | WO | claimed |
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | disclosed |
| EP-1599447-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076418-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | NR1H2, NR1H3, RXRG | AR 266/4885NPC1 116/4885RAB9A 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.